Latest news with #CinCorPharma
Daily Mail
14-07-2025
- Business
- Daily Mail
Boost for AstraZeneca after successful trial of experimental blood pressure drug
Shares in AstraZeneca rose after a successful trial of a blood pressure drug. Britain's biggest listed firm said its experimental drug Baxdrostat reduced the blood pressure of patients who have a treatment-resistant form of hypertension. AstraZeneca said it expects its annual sales for the drug to top £3.7billion. Hypertension, known as high blood pressure, affects more than 1bn globally, according to the World Health Organisation. The condition can cause heart attacks or strokes. In the late-stage trial, the drug met its main and secondary goals to show a significant reduction in systolic blood pressure at 12 weeks, when compared with a placebo treatment, AstraZeneca said. It is different to older treatments, including ACE inhibitors, as it targets aldosterone, a hormone that raises blood pressure, the company said. The drug maker bought Baxdrostat through its £1.3billion takeover of CinCor Pharma in 2023. This was part of the group's strategy to expand its treatments for heart and kidney disease. Dan Coatsworth, investment analyst at AJ Bell, said: 'Phase three drug trials are the most important events for pharmaceutical companies as they're make or break time. 'It's the final test to see if a treatment is effective and can be submitted to a regulator for approval. AstraZeneca hit the jackpot with its hypertension drug trial.' AstraZeneca shares rose 2 per cent, or 212p, to 10,662p. Reports this month suggested it is considering shifting its stock market listing to the US in what would be a major blow to the London exchange. Chief executive Pascal Soriot is reportedly weighing moving the headquarters away from the UK as well as its main stock market listing. Soriot, 66, has lambasted the UK and the rest of Europe for falling behind other countries such as the US and China in developing medicines. In April, he said that innovation in pharmaceuticals 'has mostly been funded by the US'.
Reuters
14-07-2025
- Health
- Reuters
AstraZeneca drug lowers high BP in late-stage study; shares rise
July 14 (Reuters) - AstraZeneca (AZN.L), opens new tab's experimental drug baxdrostat has been successful in lowering high blood pressure in a late-stage study of people whose condition was hard to control or treat, the Anglo-Swedish drugmaker said on Monday, sending shares up 2%. The drug met the main and secondary goals of the study at two dosages, with a statistically significant and clinically meaningful reduction in systolic blood pressure at 12 weeks when given with standard treatment, and compared with placebo, AstraZeneca said. The company added baxdrostat to its roster after it acquired CinCor Pharma in 2023 as part of its efforts to build out its pipeline of heart and kidney disease treatments. AstraZeneca shares rose 2% to 106.60 pounds per share, and were among top percentage gainers on the blue-chip FTSE 100 (.FTSE), opens new tab index in early trading. The drug works by targeting and suppressing the hormone aldosterone, which is responsible for increasing blood pressure and causing risk of heart and kidney diseases. The drug is currently also being investigated as a standalone therapy for hypertension, and as part of a combination therapy for chronic kidney disease and the prevention of heart failure in high-risk patients with hypertension.
